Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 14 homolog (ZFP14)
- Target
- ZFP14
- Molecular classification
- Transcription factor (zinc finger protein family, specifically C2H2-type and possibly containing KRAB domain)
01
Overview
Zinc finger protein 14 homolog (ZFP14/ZNF531) is a highly conserved poly-zinc finger transcription factor characterized by thirteen zinc finger domains and, typically, a KRAB domain. It is predicted to regulate transcription by binding DNA in a sequence-specific manner and is active primarily in the nucleus. ZFP14 is down-regulated in various human cancers, correlating with poor prognosis and increased expression of tumor-promoting HOXA gene cluster and pro-inflammatory cytokines. Deficiency of ZFP14 in mice causes diffuse large B-cell lymphoma, generalized organ hyperplasia, chronic inflammation, and poor survival, highlighting its critical regulatory role in gene expression and disease. No approved drugs are noted to directly target ZFP14. The molecule is a subject of interest as a disease biomarker and emerging therapeutic target in oncology and inflammation research.
- Other names
- ZFP14ZNF531KIAA1559Zfp-14Zinc finger protein 531Zinc finger protein 14 homolog
02
Mechanism of action
Modulation of transcriptional activity—either inhibition or activation via DNA binding
03
Biological functions
Regulation of gene transcription (RNA polymerase II-dependent)Repression/activation of target gene expressionControl of inflammation (suppresses abnormal cytokine expression and lymphomagenesis)Regulation of cell development and differentiation
04
Disease associations
Cancer, especially diffuse large B-cell lymphoma (DLBCL), and increased risk in Zfp14-deficient miceInflammation (regulates pro-inflammatory cytokine expression, chronic inflammation)Associated with congenital diarrhea and primary ciliary dyskinesia (rare genetic disorders)
05
Safety considerations
Zfp14-deficient animal models show systemic inflammation, liver steatosis, pancreatitis, increased susceptibility to cancer and reduced lifespan, indicating safety concerns for therapeutic modulation
06
Biomarkers
Loss or downregulation of ZFP14 may serve as a biomarker for poor prognosis in cancer, especially in DLBCL (correlates with increased HOXA gene cluster and poor outcomes)
Beyond the preview
Go deeper on Zinc finger protein 14 homolog (ZFP14).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zinc finger protein 14 homolog (ZFP14).